clinical trial · NCT04627285
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
UCB Biopharma SRL·phase3·completed·n = 48
EpilepsyLacosamide
brief summary
The purpose of the study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or NCT00938912 (SP848).
started
Dec 28, 2020
primary completion
Feb 12, 2025
completion
Feb 12, 2025
last updated
Aug 28, 2025
official title
A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol